Across TCGA pan-cancer cohorts, PHB2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PHB2 data layer compared with 23 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PHB2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PHB2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

HNSC, LIHC, and KIRP are the cancer types where PHB2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.196	0.751	.004	27	view →
LIHC	OS	Median	All	0.506	0.783	<.001	8	view →
KIRP	OS	Median	All	0.181	0.704	.044	2	view →
UCEC	DFS	Median	All	1.000	0.631	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: PHB2 tumor-vs-normal RNA expression · all PHB2 data types